



Preclinical Cancer Science Symposium

October 31, 2018

AGENDA

8:30 - 9:00 Registration and breakfast (Jimmy Fund Auditorium)

9:00 -11:15 Sessions I and II (Jimmy Fund Auditorium)

11:15 - 1:30 Poster Session and Lunch (Yawkey 306/307)

1:30 - 3:45 Sessions III-V and Prize Announcement (Jimmy Fund Auditorium)

Session I: New models and technology for developing more personalized therapies

Session Chair: Kim Stegmaier (BCH)

- **Ben Drapkin** (Dyson Lab, MGH): A patient-derived xenograft platform for co-clinical trials in a small cell lung cancer
- **Shruti Bhatt** (Letai Lab, DFCI): Individualized functional approach to tailor treatment for Acute myeloid leukemia primagrafts
- **Hui Lui** (Toker Lab, BIDMC): Identifying and targeting sporadic oncogenic gene fusions in mouse models of triple-negative breast cancer

Session II: Identifying new potential therapeutic vulnerabilities

Session Chair: Brendan Manning (HSPH)

- **Manav Gupta** (Kim Lab, BCH): Targeting BAF complex mutant lung cancers with ATR inhibition
- **Jessica Spinelli** (M. Haigis Lab, HMS): Mitochondrial compartmentalization of ammonia assimilation stimulates breast cancer proliferation
- **Matt Oser** (Kaelin Lab, DFCI): Cells lacking the RB1 tumor suppressor gene are hyperdependent on Aurora B kinase for survival

Session III: Targeting epigenetic regulators in cancer

Session Chair: Sandra McAllister (BWH)

- **Amanda Iniguez** (Stegmaier Lab, BCH): Resistance to BET bromodomain inhibition engenders tumor cell vulnerabilities associated with enhancer remodeling
- **Stephanie Guerra** (Cichowski Lab, BWH): A deregulated HOX gene axis confers an epigenetic vulnerability in KRAS mutant lung cancer

Session IV: Mechanisms that amplify or repress the immune response

Session Chair: Stephanie Dougan (DFCI)

- **Shunsuke Kitajima** (Barbie Lab, DFCI): Suppression of STING signaling in KRAS-LKB1 mutant lung cancer
- **Christopher Garris** (Pittet Lab, MGH): Successful anti-PD-1 cancer immunotherapy requires T Cell-dendritic cell crosstalk involving the cytokines in IFN-gamma and IL-12

Session V: Unexpected mechanisms of therapeutic Resistance

Session Chair: Alex Toker (BIDMC)

- **Gregory Goreczny** (McAllister Lab, BWH): Age dictates response to immune checkpoint blockade in triple-negative breast cancer
- **Haichuan Hu** (Benes Lab, MGH): Patient-derived fibroblast library delineates atlas of non-autonomous drug resistance

Steering Committee: Dave Barbie (DFCI), Cyril Benes (MGH), Karen Cichowski (BWH), Stephanie Dougan (DFCI), Kevin Haigis (BIDMC), Marcia Haigis (HMS), Aaron Hata (MGH), Brendan Manning (HSPH), Sandy McAllister (BWH), Kim Stegmaier (BCH), Alex Toker (BIDMC)